0.5360EUR+0.37%Mkt Cap: 111.20M EURP/E: —Last update: 2026-05-29
Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. The company's lead product candidate is Bexmarilimab, a novel anti-Clever-1 humanized antibody that targets a subpopulation of…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap111.20M EUR
Enterprise Value74.15M EUR
Revenue (TTM)1.31M EUR
Gross Profit1.31M EUR
Net Income (TTM)-27.26M EUR
Revenue/Share0.0120 EUR
Last Price0.5360 EUR
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees33
CountryFI
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-3.00
PEG—
EV/EBITDA-3.70
EV/Revenue56.69
P/S87.78
P/B-3.33
EPS (TTM)-0.22
EPS (Forward)-0.18
52W Range
0.43653% of range3.345
52W High3.345 EUR
52W Low0.4365 EUR
Profitability
Gross Margin100.00%
Oper. Margin-638.99%
EBITDA Margin0.00%
Profit Margin0.00%
ROE147.28%
ROA-158.73%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-17.92M EUR
CapEx (TTM)222.00K EUR
FCF Margin-866.94%
FCF Yield-10.20%
Net Debt12.36M EUR
Net Debt/EBITDA-0.62
Balance Sheet
Debt/Equity-1.33
Current Ratio0.84
Quick Ratio0.68
Book Value/Sh-0.1620 EUR
Cash/Share0.1080 EUR
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 EUR
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)1.413 EUR
Target Range0.7500 EUR – 2.500 EUR
# Analysts4
Ownership
Shares Out.199.51M
Float88.14M
Insiders16.84%
Institutions11.18%
Technical
SMA 500.4993 (+7.4%)
SMA 2001.545 (-65.3%)
Beta1.11
S&P 52W Chg27.94%
Avg Vol (30d)706.59K
Avg Vol (10d)820.60K
Technical Indicators
RSI (14)57.2
MACD0.0039
MACD Signal-0.0066
MACD Hist.+0.0105
BB Upper0.5415 EUR
BB Middle0.4937 EUR
BB Lower0.4460 EUR
BB Width19.34%
ATR (14)0.0292 EUR
Vol Ratio (20d)1.57x